A large number of studies have confirmed that anti-PD-1/PD-L1 ICIs produce better clinical therapeutic effects in patients with NSCLC, increasing the objective response and survival rates, and improving the quality of patient survival (11, 12). Here, CD274 is linked to non-small cell lung carcinoma.